The introduction of HER2‐targeted therapies, such as trastuzumab and pertuzumab, has revolutionised treatments for HER2‐positive breast cancer, providing significant survival benefits for patients [12, 13, 14]. This evidence concerns the gene ERBB2 and breast cancer.